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1 
2 
3 Summary 
4 
5 
6 Background 
7 
8 Hepatitis C virus (HCV) is a leading cause of chronic liver disease worldwide. HCV 
9 
10 predominates in people who inject drugs (PWID); a group in whom antiviral therapy 
11 
12 has previously been withheld on the basis of chaotic life style and associated risks of 
13 
14 
reinfection. New research has emerged which suggests that by specifically targeting 
15 
16 
17 HCV-infected PWID for treatment, the pool of HCV would deplete, thus reducing 
18 
19 overall transmission and eventually leading to HCV eradication. 
20 
21 
22 
23 Aim 
24 
25 
26 To outline the requirements for HCV eradication and review the evidence that this is 
27 
28 achievable. 
29 
30 
31 
32 Methods 
33 
34 
Expert review of the literature. 
35 
36 
37 
38 
39 Results 
40 
41 The achievement of HCV eradication using ‘treatment as prevention’ is supported by 
42 
43 numerous epidemiological modelling studies employing a variety of models in 
44 
45 
46 several contexts including PWID, men who have sex with men (MSM) and prisoners. 
47 
48 More recent studies also incorporate the newer, more efficacious direct-acting 
49 
50 antiviral (DAA) drugs. These drugs have been shown to be safe and effective in 
51 
52 PWID in clinical trials. There is no empirical evidence of the impact of treatment as 
53 
54 
prevention strategies on population prevalence. 
56 
57 
58 
59 
60 
3  
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1 
2 
3 Conclusions 
4 
5 This review highlights the efforts to control HCV and evaluates the possibilities of 
6 
7 
achieving eradication of HCV. Currently, the technologies required to achieve HCV 
8 
9 
10 eradication exist, but the infrastructure to deliver them is not generally available or of 
11 
12 insufficient scale outside of specific areas. Such areas are yet to demonstrate that 
13 
14 elimination is possible but results of studies in these areas are awaited. Such a 
15 
16 demonstration would be proof of principle for eradication. Although we are aspiring 
17 
18 
towards HCV eradication, elimination is the more realistic prospect. 
20 
21 
22 
23 
24 
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41 
42 
43 
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47 
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51 
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1 
2 
3 Introduction 
4 
5 
6 Hepatitis C virus (HCV) is a leading cause of chronic liver disease worldwide, 
7 
8 conferring substantial morbidity and mortality to those infected. Chronically affecting 
9 
10 ~3% of the world’s population 1, HCV has evolved into a global public health 
11 
12 problem. It is estimated that at current treatment rates, HCV will kill 380,000 people 
13 
14 
worldwide (~13% of those currently infected) by the year 2030; and over one million 
15 
16 
17 people by 2060 
2. However, despite viral hepatitis being responsible for more deaths 
18 
19 worldwide than malaria and tuberculosis combined 
3
, it commands far less 
20 
21 international attention. 
22 
23 
24 
25 
26 Clinically, the majority of HCV infections are asymptomatic until late stage disease, 
27 
28 often occurring decades after transmission. Liver cirrhosis and hepatocellular 
29 
30 carcinoma (HCC) are strongly associated with long-term HCV infection, with the 
31 
32 typical interval between HCV exposure and clinical manifestations being around 20- 
33 
34 
30 years. It is estimated that the prevalence of liver cirrhosis in untreated patients 
35 
36 
37 with chronic HCV will increase from 25% in 2010, to 45% in 2030 
4. HCV-related liver 
38 
39 cirrhosis remains the main indication for liver transplantation in developed countries 
40 
41 5, 6, 7. Chronic HCV infection is also associated with various extra-hepatic 
42 
43 manifestations 8. 
44 
45 
46 
47 
48 HCV is a blood borne virus, being absent from most bodily fluids unless they also 
49 
50 contain blood. Iatrogenic exposure remains a significant mode of transmission in 
51 
52 many developing countries 
9
, via blood, blood products and re-use of contaminated 
53 
54 
medical equipment. Significant strides have been made to minimize this route of 
56 
57 transmission in developing health care environments. The majority of new HCV 
58 
59 
60 
5  
10 
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1 
2 
3 infections worldwide occur within marginalised societal groups, predominating in 
4 
5 people who inject drugs (PWID). Acute HCV infection is often difficult to detect given 
6 
7 
the stigmatisation of at-risk groups and the generally asymptomatic nature of early 
8 
9 
infection 10. Previously, treatment for PWID with HCV was withheld on the basis of 
11 
12 chaotic lifestyle and associated risks of re-infection, making attempts at treatment 
13 
14 futile. This belief has not been substantiated, with the empirical evidence suggesting 
15 
16 good outcomes can be achieved, that PWID’s display equal, or even superior, HCV 
17 
18 
treatment outcomes to non-PWID’s 12. This has led to international guidelines now 
20 
21 recommending treatment of HCV amongst these high-risk groups following 
22 
23 individualized assessment 11. Although evidence to support such guidelines is 
24 
25 growing it is somewhat limited at present. The change in guideline position being in 
26 
27 
part driven by ensuring equity of access to treatment for those that need it. 
28 
29 
30 
31 
32 Treatment of HCV is fast changing. The arrival of the first generation of direct-acting 
33 
34 antiviral drugs (DAA’s) in 2011 changed the landscape of HCV therapeutics, with 
35 
36 more efficacious and highly tolerable drugs entering the market 
13
. The high cost of 
37 
38 
39 these DAA’s has led to the rationing of therapy based on the degree of liver fibrosis 
40 
41 in many healthcare systems. However, research is emerging suggesting that 
42 
43 specifically targeting HCV-infected PWID will deplete the pool of HCV within society 
44 
45 for transmission, preventing new infections and giving rise to the concept of 
46 
47 
‘treatment as prevention’. This could ultimately lead to the eradication of HCV. 
48 
49 
50 
51 
52 Treatment as Prevention in HCV 
53 
54 
PWID’s represent the most at-risk population for acquiring HCV infection. As such, 
56 
57 treatment as a means of prevention should focus on PWIDs. As a group, PWID 
58 
59 
60 
6  
10 
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1 
2 
3 retain a high rate of morbidity and mortality irrespective of HCV status. However, 
4 
5 with the young ages at which PWID acquire HCV infection, the ever increasing 
6 
7 
longevity of the general population means that the burden of hepatic and extra- 
8 
9 
hepatic disease will continue to rise 14. Targeting those at greatest risk of disease 
11 
12 acquisition can lead to broader community benefits and long-term cost-effectiveness. 
13 
14 Grebely and Dore reported that in 2007 there were 16 million current PWID 
15 
16 worldwide, and a 67% HCV prevalence rate amongst PWID. This equates to around 
17 
18 
10 million HCV-infected PWID worldwide, not including the additional reservoir of 
20 
21 HCV in former PWID 
14. Given that HCV transmission is driven by PWID, efforts to 
22 
23 target active PWID for antiviral therapy are strongly supported 15, 16, 17, on the basis 
24 
25 that it may prevent virus transmission. 
26 
27 
28 
29 
30 In support of this approach to HCV eradication, modelling studies by Martin and 
31 
32 colleagues have indicated that HCV chronic prevalence could be reduced by treating 
33 
34 those at risk of ongoing HCV transmission 18, 19. A more recent study from the same 
35 
36 group reviewed a number of similar theoretical modelling studies, this time in a range 
37 
38 
of global settings and target populations in the context of DAA therapy 
20
. They 
40 
41 reported that the high incidence of HCV amongst key populations such as PWID, 
42 
43 prisoners and men who have sex with men (MSM) represented an ideal opportunity 
44 
45 to curb ongoing HCV transmission. However, the authors recognised the need to test 
46 
47 
these hypotheses empirically 
20
. A number of other mathematical models have 
48 
49 
50 attempted to explore the preventative value of treating PWID for HCV. A 2013 model 
51 
52 proposed that treating as few as 15 out of 1,000 PWID annually could halve HCV 
53 
54 prevalence within 15 years 19. The model was critically dependent on the HCV 
55 
56 prevalence in the PWID population with the number needed to treat rising with 
57 
58 
59 
60 
7  
19 
30 
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1 
2 
3 increasing prevalence, so that at 25% prevalence 15 treatments per annum achieved 
4 
5 this impact but more than 100 treatments per annum were required if HCV 
6 
7 
prevalence was over 65%.  An earlier model by the same authors predicted that for a 
8 
9 
10 PWID population with a baseline chronic HCV prevalence of 20%, treatment rates of 
11 
12 5, 10, 20 or 40 per 1,000 PWID annually for 10 years can result in a reduction in 
13 
14 prevalence of 15%, 30%, 62% and 72%, respectively 
18
. 
15 
16 
17 
18 
Another 2013 study by Martin and colleagues hypothesised that when antiviral 
20 
21 treatment is combined with opiate substitution therapy (OST) and high-coverage 
22 
23 needle and syringe programs (HCNSP), significant reductions in HCV could be 
24 
25 achieved. Using a HCV transmission model, they estimated that chronic HCV 
26 
27 
prevalence could be reduced by >50% over a ten-year period. With the newer 
28 
29 
DAA’s, the authors propose that such a target becomes even more attainable 21. 
31 
32 
33 
34 The approach of treatment as prevention carries with it several ethical challenges. 
35 
36 Whereas vaccination can be applied universally, curing through drug therapy 
37 
38 
39 requires the identification of target populations. Medical screening on such a large 
40 
41 scale poses ethical dilemmas. As recently discussed by Hagan et al 
21, a false 
42 
43 positive result can be burdensome on those labelled with such a stigmatizing 
44 
45 disease. In addition to being psychologically straining for the patient, it can also lead 
46 
47 
to unnecessary treatment and resource wastage. Conversely, false negative results 
48 
49 
50 only serve to propagate disease transmission as patients are unaware of their true 
51 
52 status. Even a true positive result can impose societal repercussions as family 
53 
54 relationships, employment opportunities and insurance status are all affected. In a 
55 
56 HCV context these concerns are minimized by the high accuracy of the diagnostic 
57 
58 
59 
60 
8  
19 
28 
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1 
2 
3 tests and confirmatory lab practices. The authors also mention incentivisation 
4 
5 schemes in an effort to combat poor compliance to screening. The follow-on from 
6 
7 
testing and diagnosis is treatment, with the inconvenience of taking medications and 
8 
9 
10 risk of side effects. In conventional treatment pathways the decision for treatment is 
11 
12 taken largely by the patient for their individual benefit. However, in the treatment as 
13 
14 prevention concept the benefit of treatment is much less for the patient but for 
15 
16 society as a whole. Any societal benefit depends on a very high level of uptake, so 
17 
18 
an individuals’ priorities around treatment could be subverted to those of society, 
20 
21 with a degree of coercion.  However, a balance must be struck between voluntary 
22 
23 participation and coercion 22. 
24 
25 
26 
27 
Eradication – Can It Be Achieved? 
29 
30 In 2014, The Lancet Commission on addressing liver disease in the UK projected 
31 
32 that with the advent of these new highly effective IFN-free therapies, chronic HCV 
33 
34 
infections could be eradicated in the UK by 2030 23. It would seem that not only have 
35 
36 
37 these new antiviral treatments changed the therapeutic landscape, but they have 
38 
39 also altered the horizon for the future of HCV. 
40 
41 
42 
43 The concepts of ‘control’, ‘elimination’ and ‘eradication’ have long been the subject of 
44 
45 
46 numerous debates. Writing for the World Health Organisation in 1998, Dowdle 
47 
48 proposed the definition of ‘control’ as being a reduction in disease incidence, 
49 
50 prevalence, morbidity or mortality to a locally acceptable level; ‘elimination’ as a 
51 
52 reduction to zero of the incidence of a specified disease in a defined geographical 
53 
54 
area; and ‘eradication’ as a permanent reduction to zero of the worldwide incidence 
56 
57 of an infection such that interventions are no longer required. To this list, he added 
58 
59 
60 
9  
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1 
2 
3 ‘extinction’, defined as being an infectious agent that no longer exists in nature or 
4 
5 laboratory conditions 
24
. 
6 
7 
8 
9 
10 Dowdle went on to describe the three principal indicators of eradicability. Firstly, an 
11 
12 intervention must exist to interrupt transmission of the infectious agent. Secondly, 
13 
14 diagnostic tools of sufficient sensitivity and specificity must be universally accessible 
15 
16 to detect transmissible levels of infection. Lastly, humans must be essential to the life 
17 
18 
cycle of the infectious agent, with no ex vivo amplification 24. In the context of HCV, 
20 
21 the terms ‘eradication’ and ‘elimination’ are often used interchangeably, despite 
22 
23 regional or national elimination being a more realistic prospect for HCV in the 
24 
25 medium term. Regardless, the elimination and eradication of disease, both of which 
26 
27 
evolve from the concept of control, remain the ultimate goals of public health. To 
28 
29 
30 date, only one disease has been successfully eradicated on a global scale; smallpox 
31 
32 was declared eradicated in 1980. Polio is now only endemic in a few countries and 
33 
34 efforts are ongoing to eradicate it entirely. In both cases, eradication efforts centered 
35 
36 on prevention through vaccination and containment. When Dowdle’s principles are 
37 
38 
39 applied to HCV the evidence generates much hope, but some remaining challenges, 
40 
41 to achieve elimination. 
42 
43 
44 
45 HCV Life Cycle and Humans 
46 
47 
HCV is exclusively a human pathogen, with very few species capable of being 
48 
49 
50 infected even in experimental conditions and no meaningful zoonotic reservoir to 
51 
52 infect human hosts 
13 or facilitate amplification. So we can regard HCV as having an 
53 
54 exclusively human host for it’s life cycle and fore filling the first of Dowdle’s principles 
55 
56 24. 
57 
58 
59 
60 
10  
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1 
2 
3 
4 
5 Diagnostic Tools 
6 
7 
The diagnosis of HCV depends on antibody testing and confirmation of active 
8 
9 
10 disease by viral nucleic acid detection, usually by a PCR-based test for HCV viral 
11 
12 RNA. Both of these tests are widely available as commercial assays validated 
13 
14 against international standards. They exist as conventional blood sample-based 
15 
16 laboratory analyzed tests, as well as dried blood spot (DBS)-based tests and tests 
17 
18 
based on analysis of other bodily fluids. Additionally, they can be sent away and 
20 
21 batch tested or tested in real time at the point of care; these have been reviewed 
22 
23 elsewhere 25. So the technology to provide accurate diagnosis is widely available. 
24 
25 The only remaining challenge is to use it in the most effective way to increase the 
26 
27 
diagnosis rate and convert this to entry into treatment and cure of HCV. The current 
28 
29 
30 failure of diagnosis is evidenced when one considers that 50-70% of those with 
31 
32 chronic HCV in the US are unaware of their HCV status 
26, 27. The introduction of 
33 
34 sensitive and specific point-of-care testing kits in community settings accessed by at- 
35 
36 risk groups would provide healthcare professionals with the tools to rapidly 
37 
38 
39 determine HCV status. Many of the available testing kits circumvent the need for 
40 
41 venipuncture to be performed. This is advantageous given that PWID generally have 
42 
43 poor venous access. The use of such testing would enable case-finding in certain 
44 
45 higher prevalence settings. The benefits of point-of-care testing, i.e. result available 
46 
47 
within thirty minutes as compared to a similar sample being sent to a remote 
48 
49 
50 laboratory and available in a few days, are yet to be proven. The most important 
51 
52 issue is how diagnosis leads to treatment and cure. The pathway to treatment and 
53 
54 cure is going to be one of multiple visits to the point of care or other sites; and the 
55 
56 
57 
58 
59 
60 
11  
19 
Page 11 of 78 Alimentary Pharmacology & Therapeutic 
 
 
1 
2 
3 value of an instant test result as opposed to returning at a later date for said result 
4 
5 must be weighed in the context of entry to treatment, which is yet to be evaluated. 
6 
7 
8 
9 
10 Given that over half of PWID in the UK and USA are unaware of their true HCV 
11 
12 status 
26, 27
, testing at-risk populations to raise the number of people being treated for 
13 
14 HCV is vital to have any chance of achieving HCV elimination. Previous UK studies 
15 
16 evaluating the option of DBS testing within specialist addiction services and prisons 
17 
18 
found that HCV testing increased almost six-fold 28, 29. A recent U.S study reported 
20 
21 that in IVDU clinics that offer comprehensive screening and assessment for blood 
22 
23 borne viruses, diagnostic rates of HCV soar in PWID populations 30. A 2015 
24 
25 systematic review supports these findings, reporting that the availability of DBS 
26 
27 
testing appears to increase the uptake of HCV testing in high-risk populations 
25
. 
28 
29 
30 Hence, DBS is clearly a vital tool in the efforts to increase HCV case-finding amongst 
31 
32 PWID. DBS has been proven to be suitable for large-scale screening programs and 
33 
34 therapeutic monitoring. As such, it can be employed to increase access to care 30. 
35 
36 
37 
38 
39 A recent cost-utility analysis utilizing a dynamic mathematical model showed that 
40 
41 increasing HCV case-finding in addiction services can be cost-effective. However, 
42 
43 this does not translate directly to prison settings. Cost-effectiveness of case-finding 
44 
45 here depends on continuity of care following release 31. It has been argued that the 
46 
47 
U.S criminal justice system represents an ideal focus for HCV case-finding and 
48 
49 
50 treatment, given the high volume of HCV-infected individuals currently in contact with 
51 
52 correctional facilities 
32. However, some may argue that the way correctional facilities 
53 
54 operate would worsen treatment outcomes due to high rates of re-infection, 
55 
56 secondary to unacknowledged institutional high risk drug use. Additionally routes of 
57 
58 
59 
60 
12  
19 
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1 
2 
3 reimbursement for treatment costs may make it impossible to establish treatment 
4 
5 programs in prisons in many countries. 
6 
7 
8 
9 
10 A 2015 Canadian study evaluated the health and economic benefits conferred by 
11 
12 incorporating a one-time screening strategy for HCV in various populations. Using a 
13 
14 state-transition model, they proposed that a one-time screening program for pre- 
15 
16 selected age groups would likely be cost-effective as asymptomatic cases of HCV 
17 
18 
would be detected. They calculated that this approach could prevent at least 9 HCV- 
20 
21 related deaths per 100,000 persons screened over the lifetime of the cohort 
22 
23 analysed 33. 
24 
25 
26 
27 
So the diagnostic technology to diagnose HCV is reliable, cost-effective and widely 
28 
29 
30 available. The evidence base for modes of delivery of testing is substantial and this 
31 
32 is being translated into effective detection programs in some countries with France 
33 
34 and Australia reporting approximately 80% of their prevalent HCV populations having 
35 
36 been diagnosed 
34
. So widespread diagnosis of prevalent HCV infection is possible 
37 
38 
39 and has already been achieved in some countries. 
40 
41 
42 
43 Interruption of Transmission 
44 
45 There are multiple potential routes at which we could interrupt transmission of HCV, 
46 
47 
including primary prevention of infection and therapy to prevent further transmission. 
48 
49 
50 In primary prevention of HCV, clean needles and syringes are the mainstay but 
51 
52 developments in vaccination offer some hope for the future. In HCV therapy, 
53 
54 treatment as prevention is dependent not just on the efficacy of the therapy but also 
55 
56 on its effective delivery. 
57 
58 
59 
60 
13  
15 
35 
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1 
2 
3 
4 
5 1.   Primary prevention of infection. 
6 
7 
8 The main driver for new HCV infection is the injection of drugs with contaminated 
9 
10 needles and other injecting paraphernalia 35. Therefore, the provision of clean 
11 
12 needles and other injecting equipment, along with access to opiate replacement 
13 
14 
therapy (for opiate users), to reduce injecting frequency, should reduce the risk of 
16 
17 HCV transmission. It has been estimated that prevalence of HCV in the UK could be 
18 
19 up to 60% higher in the absence of OST and HCNSP 36. Hagan et al reported that 
20 
21 strategies combining treatment for substance misuse and instruction for safe 
22 
23 
injecting practices reduced HCV seroconversion by 75%. However, they reported 
24 
25 
26 that further research is needed to ascertain what specific interventions are most 
27 
28 effective in the different subgroups of PWID 
37. To complement the Hagan study, 
29 
30 Turner et al estimated that OST and HCNSP reduce HCV transmission by 80% in a 
31 
32 UK context 38. Nonetheless, previous modelling has suggested that OST and 
33 
34 
HCNSP alone does not prevent incident HCV infections amongst UK PWID 36. 
36 
37 Indeed, such programs have demonstrated higher success rates for HIV prevention 
38 
39 compared to HCV 14, 37. Contributing factors to this are that HCV is ten times more 
40 
41 transmissible than HIV, (in the PWID context) and HCV often survives on fomites for 
42 
43 
prolonged periods of time 39. Despite this, OST and HCNSP offer other benefits such 
44 
45 
46 as reductions in drug-related deaths and drug-related crime as well as protection 
47 
48 from other blood borne infections 
21, 40. 
49 
50 
51 
52 HCV eradication will likely not be possible without staunch efforts to limit new 
53 
54 
55 infections that are fueling the epidemic. Numerous interventions have evolved over 
56 
57 the years that serve to decrease transmission rates. As already alluded to, 
58 
59 
60 
14  
19 
30 
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1 
2 
3 community-based outreach and education programs, stemming from the HIV 
4 
5 epidemic in the 1980’s, proved beneficial in reducing the prevalence of blood borne 
6 
7 
viruses within local populations. Access to free sterile injecting equipment further 
8 
9 
10 contributed to reductions in HIV and HCV transmission. Although HCV remains very 
11 
12 high amongst PWID, the introduction of anti-HIV interventions had a profound impact 
13 
14 on HCV prevalence 
14
. However, such effective public health interventions are 
15 
16 scarce, even in many developed countries. Even where they exist, funding is poor. 
17 
18 
Edlin and Winkelstein argue that community interventions must be scaled-up if HCV 
20 
21 transmission is to be reduced 
39. In a review on the feasibility of HCV eradication in 
22 
23 the United States, they comment that needle and syringe programs only operate in 
24 
25 166 U.S cities, with 20 states not running any such programs at all. They also argue 
26 
27 
that pharmacies are critical in providing sterile needles as they would reach all 
28 
29 
populations, not just a fraction of PWID as it currently stands 39. Current U.S 
31 
32 legislation in many states restricts access to sterile needles and syringes for illicit 
33 
34 drug-use. This reflects a need for policy change in a concerted effort to stem the tide 
35 
36 of HCV. Recent changes to Californian legislation gave more power to local health 
37 
38 
39 jurisdictions, with some cities choosing to legalise non-prescription syringe sales in 
40 
41 pharmacies. A 2015 analysis demonstrated that where it was legal, more syringes 
42 
43 were obtained amongst IVDU populations. Public health policies such as this must 
44 
45 be extended to realize the true benefits it would have on HCV transmission in target 
46 
47 
populations 
41
. However, one must take into account the varied transmission profiles 
48 
49 
50 now being seen in some developed countries and any public health initiatives for the 
51 
52 provision of injecting equipment must ensure it reaches those at risk. Recent trend 
53 
54 analysis has revealed an emerging HCV epidemic in the U.S, stemming from chaotic 
55 
56 injecting habits and early prescription opioid abuse. Socioeconomic analysis reveals 
57 
58 
59 
60 
15  
19 
30 
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1 
2 
3 the epidemic to be concentrated in non-urban white males, who often have very 
4 
5 limited access to sterile injecting equipment and injecting advice from experienced 
6 
7 
IVDU 42 as this is occurring in areas without previous significant injecting drug use. 
8 
9 
10 Different patterns of drug abuse may change the benefits of the treatment as 
11 
12 prevention approach. 
13 
14 
15 
16 Although needle-sharing is a major aspect of HCV transmission, other injection 
17 
18 
paraphernalia have been strongly implicated in the spread of the virus. For example, 
20 
21 the sharing of cookers, filtration cotton and water can also permit viral transmission 
22 
23 43. An earlier study calculated that 54% of HCV infections in PWID who did not share 
24 
25 needles could be attributed to other injecting equipment 
44
. The provision of sterile 
26 
27 
paraphernalia in Scotland is anticipated to reduce HCV transmission amongst PWID, 
28 
29 
but results from this natural experiment are awaited 43. However, earlier studies 
31 
32 evaluating the risks of HCV transmission amongst PWID who share injecting 
33 
34 equipment have failed to quantify the contribution that this route of infection is having 
35 
36 on HCV spread 
45
. Indeed, one 2014 study concluded that, although injecting risk 
37 
38 
39 behaviour is clearly reduced by OST and NSP, comparatively little review-level 
40 
41 evidence exists to support such a trend for HCV transmission amongst PWID’s 
46. 
42 
43 
44 
45 2.   Vaccination 
46 
47 
48 In most infectious diseases that have been considered for elimination a vaccine has 
49 
50 been available. However, this is not essential as evidenced by the near eradication 
51 
52 of the Guinea worm without even drug therapy 47. Of course vaccine development 
53 
54 
55 seems logical. It can be reasonably argued that due to the asymptomatic nature of 
56 
57 the virus, and the fact that most people are unaware of their HCV status, vaccination 
58 
59 
60 
16  
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1 
2 
3 is perhaps the most effective way of eradicating HCV 
10
. A universal vaccine could 
4 
5 not only prevent primary HCV infection, but may also prevent re-infection after cure 
6 
7 
following DAA therapy. This latter use has implications for those with ongoing risk of 
8 
9 
HCV exposure, such as PWID 48. It is estimated that even if pricing of DAA’s were 
11 
12 1,000-fold lower to benefit low-income nations, the costs of extensive HCV screening 
13 
14 and DAA distribution would exceed those of a universal vaccination program 
49
. 
15 
16 Results from several vaccine trials are eagerly awaited. In one such study, Swadling 
17 
18 
et al describe the development of a highly immunogenic vaccine for HCV. By utilizing 
20 
21 the critical role that T cell immunity plays in antiviral control, they report having 
22 
23 produced a potent T cell vaccine that prevents chronic infection by incorporating 
24 
25 chimpanzee adenoviral and MVA vectors to prime and boost T cell memory. The first 
26 
27 
efficacy study of ChAd3NSmut/MVA-NSmut in IVDU’s has recently started in the U.S 
28 
29 
(NCT01436357) 50. However, results from these studies are forthcoming and 
31 
32 historically, such T cell vaccines have had more limited efficacy than antibody based 
33 
34 vaccines in clinical trials. 
35 
36 
37 
38 
3.   HCV therapy 
39 
40 
41 HCV antiviral therapy has undergone a revolution, moving very rapidly from IFN- 
42 
43 
based therapies with cure rates of 40-70% depending on genotype, to the advent of 
44 
45 
46 DAA’s achieving cure rates in excess of 90% for all genotypes with treatment 
47 
48 duration reduced to as little as eight weeks. The development of these newer DAA’s 
49 
50 has long been impeded by the lack of an effective cell culture system for HCV 
51 
52 proliferation 51. The availability of high-throughput virological assays to characterise 
53 
54 
55 the various stages of the HCV replication cycle have enabled the identification of 
56 
57 more specific antiviral targets 
52, 53. This development, combined with changes in the 
58 
59 
60 
17  
10 
37 
57 
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1 
2 
3 definition of sustained virological response (SVR), has generated the momentum for 
4 
5 the rapid change in the field. The European Association for Study of Liver (EASL) 
6 
7 
describes the endpoint of therapy as undetectable HCV RNA 24 weeks after the end 
8 
9 
of the treatment course (SVR24), defined as <15 IU/mL 11. In a long-term follow-up 
11 
12 study of HCV-infected patients treated with PEG-IFN-2a and ribavirin (n = 1,343), a 
13 
14 durable SVR24 of 99.1% was retained once achieved 
54
. Such data suggests that 
15 
16 
HCV recurrence is rare in patients who achieve an SVR, and that from a virologic 
17 
18 
19 standpoint, such patients can be regarded as cured. The validity of measuring HCV 
20 
21 RNA 12 weeks after completion of treatment (SVR12) has been evaluated and 
22 
23 approved by regulators in the U.S and Europe, as an equivalent end point 11. 
24 
25 
26 
27 
28 The currently available new DAA’s are split into three classes defined by their HCV 
29 
30 target protein: the protease inhibitors targeted against the NS3/4a protease; and the 
31 
32 NS5a complex inhibitors and polymerase inhibitors, which are directed against the 
33 
34 NS5b protein. This latter class can be further divided into nucleotide and non- 
35 
36 
nucleotide inhibitors. Initial protease inhibitors, and to a lesser extent NS5a 
38 
39 inhibitors, are genotype specific. However, newer pan-genotypic DAA’s with superior 
40 
41 efficacy, lower adverse effect profiles and shorter therapy durations are constantly 
42 
43 emerging 13. 
44 
45 
46 
47 
48 Access to treatment has been widened with the advent of these new drugs. 
49 
50 Previously, IFN-based therapy was contraindicated in patients with many co- 
51 
52 morbidities including decompensated cirrhosis 35. Thus, with the new DAA’s therapy 
53 
54 can now be given to patients in whom it may have previously been contraindicated. 
55 
56 
This also applies to PWID populations, where concerns about adherence to safety 
58 
59 
60 
18  
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1 
2 
3 monitoring was considered a relative contraindication to therapy, despite studies 
4 
5 showing this was not an issue. Currently, concerns are expressed about how robust 
6 
7 
the new all-oral regimens are if adherence is suboptimal in patients with more 
8 
9 
10 chaotic lifestyles, leaving them at risk of developing viral resistance. Trials of DAA’s 
11 
12 in PWID to date have shown treatment remains highly effective in this population 
55,
 
13 
14 56, 57. The full impact of DAA’s will only be appreciated once innovative approaches 
15 
16 to engage more HCV-infected individuals into antiviral therapy are practiced. 
17 
18 
19 
20 
21 4.  Delivery of HCV therapy- Pathway to Eradication 
22 
23 
The delivery of therapy to patients is key to its efficacy. Complex care pathways, 
24 
25 
26 based in, or outreaching from secondary or tertiary care, have been developed to 
27 
28 deliver IFN-based therapy to patients. Such care pathways focus on managing the 
29 
30 side effects of therapy safely. Chaotic unstable patients such as PWID have not 
31 
32 made it through these therapy pathways in significant numbers and such patients 
33 
34 
35 that do are atypical. The aim of these pathways has been to prevent advanced liver 
36 
37 disease by curing HCV infection before cirrhosis develops. So the episode of 
38 
39 treatment can be delayed until the patient is considered suitable, by the constraints 
40 
41 of the treatment pathway. This is in marked contrast to the situation if treatment as 
42 
43 
prevention is the aim of therapy, where early therapy at the earliest possible time in 
44 
45 
46 the duration of infection would give the optimum outcome. So the pathway to 
47 
48 treatment has to be receptive to the patient. 
49 
50 
51 
52 Clinical networks are a much vaunted solution to the problems associated with 
53 
54 
55 treatment of HCV. In England they are a very secondary care-based solution to allow 
56 
57 patients to be treated at hospitals closer to their locality, but still controlling 
58 
59 
60 
19  
19 
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1 
2 
3 availability of drug therapy centrally. In Scotland’s HCV action plan, managed care 
4 
5 networks were a central plank to achieve the integration of primary and secondary 
6 
7 
care with third sector providers of health care around patients with or at risk of HCV 
8 
9 
10 into a cohesive and seamless treatment pathway. This integration was fundamental 
11 
12 to the success of the Scottish action plan, the implementation of this is described 
13 
14 and illustrated in the report by Tait et al 
58
. Thus networks can achieve improvement 
15 
16 in care, particularly when working across healthcare boundaries and accessing 
17 
18 
difficult-to-reach patient populations. However, all key stakeholders in the area need 
20 
21 to be a part of the network, working together to an agreed strategic aim. The MCN 
22 
23 model is ideally suited to a treatment as prevention strategy. 
24 
25 
26 
27 
PWID are a largely stigmatized group who have limited access to conventional 
28 
29 
30 health care. Often as a result of homelessness and deprivation, many patients lack a 
31 
32 means of communication with conventional healthcare providers. However, they are 
33 
34 often in regular contact with other services in a variety of contexts. For example: 
35 
36 needle exchange programs in the community which dispense both sterile injecting 
37 
38 
39 equipment and advice on safe injecting practices; and pharmacies which administer 
40 
41 methadone to those on opiate substitution programs. These points of contact 
42 
43 represent an ideal opportunity to target PWID for HCV treatment. Pilot studies show 
44 
45 that with the new DAA’s, with their reduced need for regular blood monitoring and 
46 
47 
fewer side-effects, the clinical and para-clinical staff within these facilities such as 
48 
49 
50 pharmacists and drug workers are keen and able to take on a lead role in 
51 
52 assessment and provision of anti-HCV therapy as part of managed care networks 
59. 
53 
54 These managed care networks provide the clinical supervision they need to deliver a 
55 
56 protocol-based HCV treatment pathway. The initial SVR rates from such pathways 
57 
58 
59 
60 
20  
19 
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1 
2 
3 match clinical trials and are much more inclusive of a broader group of patients from 
4 
5 a PWID background, which is vital to a treatment as prevention strategy. 
6 
7 
8 
9 
10 In addition to OST centers (e.g. pharmacies) and NSP facilities, prisons should also 
11 
12 be considered as an opportunity to treat. Given the high numbers and proportions of 
13 
14 PWID in correctional facilities, prisoners represent an ideal target population for 
15 
16 treatment as prevention. As with targeting PWID’s in general, targeting prisoners 
17 
18 
poses its own challenges and ethical considerations. A 2015 letter by Levy and 
20 
21 Larney highlighted the issues of treatment as prevention in correctional settings. 
22 
23 They argue that the imbalance of power between prisoners and custodial staff may 
24 
25 translate to a curtailing of civil liberties 
60
. In such circumstances, how can we be 
26 
27 
sure that consent to screening and treatment is truly voluntary? Adding to this, Martin 
28 
29 
30 and colleagues emphasize the need for continuity of care amongst prisoners after 
31 
32 release or transfer for this approach to HCV prevention to be cost-effective 
61. A 
33 
34 recent review of treatment outcomes in prisoners treated in Scotland has shown a 
35 
36 strong negative correlation between liberation during treatment and SVR. This work 
37 
38 
39 was using IFN-based therapy and so should be less of an issue with new DAA- 
40 
41 based therapy of shorter duration 
62. In terms of primary prevention Levy and Larney 
42 
43 also called for greater access to harm reduction services such as needle exchange 
44 
45 programs within prisons, arguing that such services exist in community settings for 
46 
47 
PWID. As such, those who successfully complete treatment can protect themselves 
48 
49 
50 from re-infection and thus increase the effectiveness of this HCV eradication strategy 
51 
52 
60. It should be noted, however, that a 2013 study found that in a sample of 5,076 
53 
54 surveyed prisoners in Scotland, the risk of HCV transmission was lower amongst 
55 
56 prisoners compared to Scottish people who inject in the community. The authors 
57 
58 
59 
60 
21  
10 
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1 
2 
3 propose that this is due to the low incidence of in-prison injecting, although they 
4 
5 concede that some under-reporting is likely. As such, the authors suggest that low 
6 
7 
HCV incidence amongst prison populations does not depend on the introduction of 
8 
9 
needle exchange programs 63. The major issue around provision of needle exchange 
11 
12 in prisons is the potential for their use as weapons against staff which has led prison 
13 
14 officer unions to object on health and safety grounds. 
15 
16 
17 
18 
The major criticism of treatment as prevention strategies in PWID is the impact on 
20 
21 injecting behaviour and the risk of re-infection. Regarding the interplay between HCV 
22 
23 treatment and PWID behaviour, it has been established that antiviral therapy does 
24 
25 not increase illicit drug use. Intermittent injecting during treatment has also been 
26 
27 
shown to have no influence over regimen adherence, completion of treatment, or 
28 
29 
30 SVR attainment. Contrary to this, more regular injecting has been associated with 
31 
32 lower SVR rates and discontinuation of treatment 
14. In an effort to better understand 
33 
34 injecting behaviours and how they relate to re-infection risk post-SVR, Valerio and 
35 
36 colleagues conducted an analysis of 1,170 PWID who attained an SVR over a 
37 
38 
twenty-year period (1992-2012) 
64
. They reported that an increasing minority of 
40 
41 PWID who attain an SVR are at an elevated risk of re-infection or death as a result of 
42 
43 high intensity injecting behaviour. In agreement with EASL recommendations 11, the 
44 
45 authors advocate for the on-going monitoring of high-risk patients post-SVR 64. 
46 
47 
However, evidence suggests that PWID who achieve an SVR are more likely to 
48 
49 
pursue a healthy lifestyle 
65
. The Valerio study also voiced concern that re-infection 
51 
52 rates amongst PWID will rise as HCV treatment is scaled-up 
64. Commentary from 
53 
54 Hellard and Scott (2015) postulated that many of the current models measuring the 
55 
56 outcomes of HCV treatment as prevention incorporate high levels of re-infection into 
57 
58 
59 
60 
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1 
2 
3 their modelling, thus overstating the re-infection risk. Whilst it is established that HCV 
4 
5 re-infection is common out-with treatment settings, re-infection after antiviral therapy 
6 
7 
is considerably lower 66. A meta-analysis by Aspinall et al calculated the pooled risk 
8 
9 
10 of re-infection amongst five cohorts of PWID (n = 131) to be 2.4 (CI = 0.9-6.1) per 
11 
12 100 person years 
67
. However, a 2016 study reported an 11% re-infection rate in a 
13 
14 multicentre trial follow-up of PWID’s infected with genotypes 2 or 3 
68
. This highlights 
15 
16 possible variations in the range of reinfections. Emergent data from the ERADICATE 
17 
18 
trial will provide more information on reinfection rates in PWID’s undergoing anti- 
20 
21 HCV therapy. A more recent study suggested that targeting HCV treatment by 
22 
23 stratifying the level of injection drug-use could enhance benefits at the population 
24 
25 level 
69
. The authors reported that HCV treatment is best determined by its 
26 
27 
prevalence within the population; when >50% of all exchanged syringes are 
28 
29 
30 contaminated with HCV they recommend treating low-risk PWID first. Conversely, 
31 
32 below this threshold, treating high-risk PWID first appeared to produce the greatest 
33 
34 societal benefits 69. Indeed, it has been shown that targeting the injecting network 
35 
36 provides greater population health benefit than treating PWID randomly for their HCV 
37 
38 70
.  Studies such as this support the idea that PWID’s should not be excluded from 
40 
41 treatment based on their apparently risky behaviour. A further study by Martin and 
42 
43 colleagues suggested that treating current injectors is more cost-effective than 
44 
45 treating ex- or non-injectors when the chronic HCV prevalence is less than 60% 71. 
46 
47 
48 
49 
50 Eradication – Is It Cost-Effective? 
51 
52 Relative to the expense of long-term complications associated with HCV infection, 
53 
54 
the price of DAA’s is considered cost-effective 22. The bulk of the health costs and 
56 
57 health consequences associated with HCV infection are due to end stage liver 
58 
59 
60 
23  
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39 
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1 
2 
3 disease late in the natural history of infection. This has led some to suggest that 
4 
5 treatment should be restricted to patients with more advanced disease only. As even 
6 
7 
in high-income nations the cost of DAA’s may prohibit their widespread uptake, due 
8 
9 
10 to affordability, relative to other demands on health budgets. Cost-effective 
11 
12 evaluations are needed to verify how best to allocate resources and services. A 2015 
13 
14 study aimed to forecast population-level outcomes from alternative treatment 
15 
16 strategies in a resource-rich setting 
72
. Using a simulation model and projecting 
17 
18 
outcomes to 2030, trends in HCV incidence and severe liver morbidity was 
20 
21 extrapolated according to treatment strategies that prioritised either PWID or patients 
22 
23 with moderate/advanced liver fibrosis. The authors concluded that no single 
24 
25 approach to the treatment of HCV in an era of IFN-free therapies addressed all 
26 
27 
public health concerns. Prioritising PWID for treatment results in substantially 
28 
29 
30 reduced HCV incidence and transmission rates in the population, but fails to address 
31 
32 the impact of liver disease. Conversely, suboptimal reductions in HCV incidence 
33 
34 occurs when those with moderate/advanced liver disease are targeted for priority 
35 
36 treatment. It is projected that by specifically targeting active PWID, incident HCV 
37 
38 
infection can be reduced to <50 cases per year by 2025 
72
. The conclusion that can 
40 
41 be drawn from this paper was that a twin track strategy that targeted active PWID 
42 
43 and those with evidence of hepatic fibrosis would be most cost-effective, but would 
44 
45 leave the short fall in treatment on those with mild disease who were not injecting, a 
46 
47 
strategy that may not be acceptable to the general population. These estimates 
48 
49 
50 support the previous modelling studies by Martin and colleagues described above. 
51 
52 The high cost of anti-HCV therapy makes a more targeted treatment approach more 
53 
54 economically beneficial. As such, epidemiological data on PWID populations must be 
55 
56 upgraded on a country by country basis to allow a planned strategy 73. As already 
57 
58 
59 
60 
24  
10 
19 
55 
Alimentary Pharmacology & Therapeutic Page 24 of 78 
 
 
1 
2 
3 discussed, it is unlikely that substantial reductions in HCV prevalence would be 
4 
5 achievable with OST and HCNSP alone. However, expansion of OST and NSP 
6 
7 
coverage would reduce the number of PWID requiring HCV treatment, and be highly 
8 
9 
cost-effective thus making a target HCV prevalence reduction easier to achieve 14. 
11 
12 This supports the idea that HCV eradication policy must be built upon scaled-up 
13 
14 community outreach projects. While the health economic analysis supports the idea 
15 
16 of treatment as prevention, and shows it to be a cost effective, it may not be 
17 
18 
achievable due to the affordability issues surround such a relatively common disease 
20 
21 with such a currently expensive therapy. There is already prioritisation of HCV 
22 
23 therapy for patients with advanced fibrosis in many countries, with patients with 
24 
25 milder disease waiting for therapy. To further prioritise active PWID over other 
26 
27 
patients with mild disease may not be acceptable to health care providers and 
28 
29 
30 payers. 
31 
32 
33 
34 Conclusion 
35 
36 
37 The growing burden of chronic HCV infection presents a significant public health 
38 
39 concern. With the advent of highly efficacious and tolerable DAA’s, the concept of 
40 
41 treatment as prevention is gaining credence and efforts to scale-up access to 
42 
43 treatment have been developed. 
44 
45 
46 
47 
48 Although global eradication of HCV via targeted treatment is highly desirable, current 
49 
50 limitations render it improbable at this point in time; with regional elimination being a 
51 
52 more realistic prospect. Sub-optimal coverage of harm reduction services worldwide, 
53 
54 
the lack of an effective vaccine, and the high baseline HCV prevalence in many 
56 
57 places makes HCV eradication very difficult to accomplish. Despite this, modelling 
58 
59 
60 
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1 
2 
3 studies by Martin and colleagues show that lower treatment uptake is required to 
4 
5 achieve a more substantial reduction in HCV prevalence when the baseline 
6 
7 
prevalence is below a certain threshold. Increased access to harm reduction 
8 
9 
10 services may drive the local HCV prevalence low enough to allow targeted treatment 
11 
12 to be successful. 
13 
14 
15 
16 Perhaps the most important prevention strategy is the implementation of HCV testing 
17 
18 
so as to identify those in need of treatment. Solutions must be formulated to 
20 
21 overcome barriers to care. In this way, more patients eligible to be treated are 
22 
23 identified and managed accordingly. Early identification, using more accurate 
24 
25 diagnostic tools, will be essential to prevent the onward transmission of HCV 
10
. 
26 
27 
28 
29 
30 Although technically feasible, HCV eradication will require a galvanised effort from 
31 
32 not only practitioners and healthcare policy makers, but also the patients 
33 
34 themselves. To achieve HCV eradication via treatment on a global scale, PWID must 
35 
36 be given increased access to affordable treatment.  Ensuring affordability of anti- 
37 
38 
39 HCV therapy will be critical in the pursuit of eradicability. 
40 
41 
42 
43 
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1 
2 
3 Summary 
4 
5 
6 Background 
7 
8 Hepatitis C virus (HCV) is a leading cause of chronic liver disease worldwide. HCV 
9 
10 predominates in people who inject drugs; a group in whom antiviral therapy has 
11 
12 previously been withheld on the basis of chaotic lifestyles and associated risks of 
13 
14 
reinfection. New research has emerged which suggests that by specifically targeting 
15 
16 
17 HCV-infected people who inject drugs for treatment, the pool of HCV would deplete, 
18 
19 thus reducing overall transmission and eventually leading to HCV eradication. 
20 
21 
22 
23 Aim 
24 
25 
26 To outline the requirements for HCV eradication and review the evidence that this is 
27 
28 achievable. 
29 
30 
31 
32 Methods 
33 
34 
Expert review of the literature. 
35 
36 
37 
38 
39 Results 
40 
41 The achievement of HCV eradication using ‘treatment as prevention’ is supported by 
42 
43 numerous epidemiological modelling studies employing a variety of models in 
44 
45 
46 several contexts including people who  inject drugs, men who have sex with men 
47 
48 and prisoners. More recent studies also incorporate the newer, more efficacious 
49 
50 direct-acting antiviral drugs. These drugs have been shown to be safe and effective 
51 
52 in people who inject drugs in clinical trials. There is no empirical evidence of the 
53 
54 
impact of treatment as prevention strategies on population prevalence. 
56 
57 
58 
59 
60 
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1 
2 
3 Conclusions 
4 
5 This review highlights the efforts to control HCV and evaluates the possibilities of 
6 
7 
achieving eradication of HCV. Currently, the technologies required to achieve HCV 
8 
9 
10 eradication exist, but the infrastructure to deliver them is not generally available or of 
11 
12 insufficient scale outside of specific areas. Such areas are yet to demonstrate that 
13 
14 elimination is possible, but results of studies in these areas are awaited. Such a 
15 
16 demonstration would be proof of principle for eradication. Although we are aspiring 
17 
18 
towards HCV eradication, elimination is the more realistic prospect. 
20 
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41 
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1 
2 
3 Introduction 
4 
5 
6 Hepatitis C virus (HCV) is a leading cause of chronic liver disease worldwide, 
7 
8 conferring substantial morbidity and mortality to those infected. Chronically affecting 
9 
10 ~3% of the world’s population 1, HCV has evolved into a global public health 
11 
12 problem. It is estimated that at current treatment rates, HCV will kill 380,000 people 
13 
14 
worldwide (~13% of those currently infected) by the year 2030; and over one million 
15 
16 
17 people by 2060 
2. However, despite viral hepatitis being responsible for more deaths 
18 
19 worldwide than malaria and tuberculosis combined 
3
, it commands far less 
20 
21 international attention. 
22 
23 
24 
25 
26 Clinically, the majority of HCV infections are asymptomatic until late stage disease, 
27 
28 often occurring decades after transmission. Liver cirrhosis and hepatocellular 
29 
30 carcinoma are strongly associated with long-term HCV infection, with the typical 
31 
32 interval between HCV exposure and clinical manifestations being around 20-30 
33 
34 
years. It is estimated that the prevalence of liver cirrhosis in untreated patients with 
35 
36 
37 chronic HCV will increase from 25% in 2010, to 45% in 2030 
4. HCV-related liver 
38 
39 cirrhosis remains the main indication for liver transplantation in developed countries 
40 
41 5, 6, 7. Chronic HCV infection is also associated with various extra-hepatic 
42 
43 manifestations 8. 
44 
45 
46 
47 
48 HCV is a blood borne virus, being absent from most bodily fluids unless they also 
49 
50 contain blood. Iatrogenic exposure remains a significant mode of transmission in 
51 
52 many developing countries 
9
, via blood, blood products and re-use of contaminated 
53 
54 
medical equipment. Significant strides have been made to minimize this route of 
56 
57 transmission in developing health care environments. The majority of new HCV 
58 
59 
60 
5  
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1 
2 
3 infections worldwide occur within marginalised societal groups, predominating in 
4 
5 people who inject drugs. Acute HCV infection is often difficult to detect given the 
6 
7 
stigmatisation of at-risk groups and the generally asymptomatic nature of early 
8 
9 
infection 10. Previously, treatment for HCV-infected people who inject drugs was 
11 
12 withheld on the basis of chaotic lifestyles and associated risks of re-infection, which it 
13 
14 was believed  maked attempts at treatment futile. This belief has not been 
15 
16 substantiated, with the empirical evidence suggesting good outcomes can be 
17 
18 
achieved; that people who inject drugs display equal, or even superior, HCV 
20 
21 treatment outcomes to groups from other routes of infection 
12. This has led to 
22 
23 international guidelines now recommending treatment of HCV amongst these high- 
24 
25 risk groups following individualized assessment 
11
. Although evidence to support 
26 
27 
such guidelines is growing it is somewhat limited at present. The change in guideline 
28 
29 
30 position being in part driven by ensuring equity of access to treatment for those that 
31 
32 need it. 
33 
34 
35 
36 Treatment of HCV is fast changing. The arrival of the first generation of direct-acting 
37 
38 
39 antiviral drugs in 2011 changed the landscape of HCV therapeutics, with more 
40 
41 efficacious and highly tolerable drugs entering the market 
13. The high cost of these 
42 
43 newer drugs has led to the rationing of therapy based on the degree of liver fibrosis 
44 
45 in many healthcare systems. However, research is emerging suggesting that 
46 
47 
specifically targeting HCV-infected people who inject drugs will deplete the pool of 
48 
49 
50 HCV within society for transmission, preventing new infections and giving rise to the 
51 
52 concept of ‘treatment as prevention’. This could ultimately lead to the eradication of 
53 
54 HCV. 
55 
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1 
2 
3 
4 
5 Treatment as Prevention in HCV 
6 
7 
8 People who inject drugs represent the most at-risk population for acquiring HCV 
9 
10 infection. As such, treatment as a means of prevention should focus on this 
11 
12 population group. As a group, people who inject drugs retain a high rate of morbidity 
13 
14 
and mortality irrespective of HCV status. However, with the young ages at which 
15 
16 
17 intravenous drug users acquire HCV infection, the ever increasing longevity of the 
18 
19 general population means that the burden of hepatic and extra-hepatic disease will 
20 
21 continue to rise 14. Targeting those at greatest risk of disease acquisition can lead to 
22 
23 broader community benefits and long-term cost-effectiveness. Grebely and Dore 
24 
25 
26 reported that in 2007 there were 16 million current intravenous drug users worldwide, 
27 
28 and a 67% HCV prevalence rate within this group. This equates to around 10 million 
29 
30 HCV-infected people who inject drugs worldwide, not including the additional 
31 
32 reservoir of HCV in former injection drug users 14. Given that HCV transmission is 
33 
34 
driven by people who inject drugs, efforts to target active injectors of drugs for 
35 
36 
37 antiviral therapy are strongly supported 
15, 16, 17, on the basis that it may prevent virus 
38 
39 transmission. 
40 
41 
42 
43 In support of this approach to HCV eradication, modelling studies by Martin and 
44 
45 
46 colleagues have indicated that HCV chronic prevalence could be reduced by treating 
47 
48 those at risk of ongoing HCV transmission 
18, 19. A more recent study from the same 
49 
50 group reviewed a number of similar theoretical modelling studies, this time in a range 
51 
52 of global settings and target populations in the context of direct-acting antiviral 
53 
54 
therapy 20. They reported that the high incidence of HCV amongst key populations 
56 
57 such as people who inject drugs, men who have sex with men and prisoners 
58 
59 
60 
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1 
2 
3 represented an ideal opportunity to curb ongoing HCV transmission. However, the 
4 
5 authors recognised the need to test these hypotheses empirically 
20
. A number of 
6 
7 
other mathematical models have attempted to explore the preventative value of 
8 
9 
10 treating people who inject drugs for HCV. A 2013 model proposed that treating as 
11 
12 few as 15 out of 1,000 people who inject drugs annually could halve HCV prevalence 
13 
14 within 15 years 
19
. The model was critically dependent on the HCV prevalence within 
15 
16 this  population, with the number needed to treat rising with increasing prevalence; 
17 
18 
so that at 25% prevalence 15 treatments per annum achieved this impact, but more 
20 
21 than 100 treatments per annum were required if HCV prevalence was over 65%.  An 
22 
23 earlier model by the same authors predicted that for a population of intravenous drug 
24 
25 users with a baseline chronic HCV prevalence of 20%, treatment rates of 5, 10, 20 or 
26 
27 
40 per 1,000 drug injectors annually for 10 years can result in a reduction in 
28 
29 
prevalence of 15%, 30%, 62% and 72%, respectively 18. 
31 
32 
33 
34 Another 2013 study by Martin and colleagues hypothesised that when antiviral 
35 
36 treatment is combined with opiate substitution therapy and high-coverage needle 
37 
38 
39 and syringe programs, significant reductions in HCV could be achieved. Using a 
40 
41 HCV transmission model, they estimated that chronic HCV prevalence could be 
42 
43 reduced by >50% over a ten-year period. With the newer direct-acting antiviral 
44 
45 drugs, the authors propose that such a target becomes even more attainable 21. 
46 
47 
48 
49 
50 The approach of treatment as prevention carries with it several ethical challenges. 
51 
52 Whereas vaccination can be applied universally, curing through drug therapy 
53 
54 requires the identification of target populations. Medical screening on such a large 
55 
56 scale poses ethical dilemmas. As recently discussed by Hagan et al 21, a false 
57 
58 
59 
60 
8  
19 
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1 
2 
3 positive result can be burdensome on those labelled with such a stigmatizing 
4 
5 disease. In addition to being psychologically straining for the patient, it can also lead 
6 
7 
to unnecessary treatment and resource wastage. Conversely, false negative results 
8 
9 
10 only serve to propagate disease transmission as patients are unaware of their true 
11 
12 status. Even a true positive result can impose societal repercussions as family 
13 
14 relationships, employment opportunities and insurance status are all affected. In a 
15 
16 HCV context these concerns are minimized by the high accuracy of the diagnostic 
17 
18 
tests and confirmatory lab practices. The authors also mention incentivisation 
20 
21 schemes in an effort to combat poor compliance to screening. The follow-on from 
22 
23 testing and diagnosis is treatment, with the inconvenience of taking medications and 
24 
25 risk of side effects. In conventional treatment pathways the decision for treatment is 
26 
27 
taken largely by the patient for their individual benefit. However, in the treatment as 
28 
29 
30 prevention concept the benefit of treatment is much less for the patient but for 
31 
32 society as a whole. Any societal benefit depends on a very high level of uptake, so 
33 
34 an individuals’ priorities around treatment could be subverted to those of society, 
35 
36 with a degree of coercion.  However, a balance must be struck between voluntary 
37 
38 
participation and coercion 
22
. 
40 
41 
42 
43 Eradication – Can It Be Achieved? 
44 
45 
46 In 2014, The Lancet Commission on addressing liver disease in the UK projected 
47 
48 that with the advent of these new highly effective IFN-free therapies, chronic HCV 
49 
50 infections could be eradicated in the UK by 2030 23. It would seem that not only have 
51 
52 these new antiviral treatments changed the therapeutic landscape, but they have 
53 
54 
also altered the horizon for the future of HCV. 
56 
57 
58 
59 
60 
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1 
2 
3 The concepts of ‘control’, ‘elimination’ and ‘eradication’ have long been the subject of 
4 
5 numerous debates. Writing for the World Health Organisation in 1998, Dowdle 
6 
7 
proposed the definition of ‘control’ as being a reduction in disease incidence, 
8 
9 
10 prevalence, morbidity or mortality to a locally acceptable level; ‘elimination’ as a 
11 
12 reduction to zero of the incidence of a specified disease in a defined geographical 
13 
14 area; and ‘eradication’ as a permanent reduction to zero of the worldwide incidence 
15 
16 of an infection such that interventions are no longer required. To this list, he added 
17 
18 
‘extinction’, defined as being an infectious agent that no longer exists in nature or 
20 
21 laboratory conditions 
24. 
22 
23 
24 
25 Dowdle went on to describe the three principal indicators of eradicability. Firstly, an 
26 
27 
intervention must exist to interrupt transmission of the infectious agent. Secondly, 
28 
29 
30 diagnostic tools of sufficient sensitivity and specificity must be universally accessible 
31 
32 to detect transmissible levels of infection. Lastly, humans must be essential to the life 
33 
34 cycle of the infectious agent, with no ex vivo amplification 24. In the context of HCV, 
35 
36 the terms ‘eradication’ and ‘elimination’ are often used interchangeably, despite 
37 
38 
39 regional or national elimination being a more realistic prospect for HCV in the 
40 
41 medium term. Regardless, the elimination and eradication of disease, both of which 
42 
43 evolve from the concept of control, remain the ultimate goals of public health. To 
44 
45 date, only one disease has been successfully eradicated on a global scale; smallpox 
46 
47 
was declared eradicated in 1980. Polio is now only endemic in a few countries and 
48 
49 
50 efforts are ongoing to eradicate it entirely. In both cases, eradication efforts centered 
51 
52 on prevention through vaccination and containment. When Dowdle’s principles are 
53 
54 applied to HCV the evidence generates much hope, but some remaining challenges, 
55 
56 to achieve elimination. 
57 
58 
59 
60 
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1 
2 
3 
4 
5 HCV Life Cycle and Humans 
6 
7 
HCV is exclusively a human pathogen, with very few species capable of being 
8 
9 
10 infected even in experimental conditions and no meaningful zoonotic reservoir to 
11 
12 infect human hosts 
13 
or facilitate amplification. So we can regard HCV as having an 
13 
14 exclusively human host for it’s life cycle and fore filling the first of Dowdle’s principles 
15 
16 24. 
17 
18 
19 
20 
21 Diagnostic Tools 
22 
23 The diagnosis of HCV depends on antibody testing and confirmation of active 
24 
25 disease by viral nucleic acid detection, usually by a PCR-based test for HCV viral 
26 
27 
RNA. Both of these tests are widely available as commercial assays validated 
28 
29 
30 against international standards. They exist as conventional blood sample-based 
31 
32 laboratory analyzed tests, as well as dried blood spot-based tests and tests based 
33 
34 on analysis of other bodily fluids. Additionally, they can be sent away and batch 
35 
36 tested or tested in real time at the point of care; these have been reviewed 
37 
38 
elsewhere 
25
. So the technology to provide accurate diagnosis is widely available. 
40 
41 The only remaining challenge is to use it in the most effective way to increase the 
42 
43 diagnosis rate and convert this to entry into treatment and cure of HCV. The current 
44 
45 failure of diagnosis is evidenced when one considers that 50-70% of those with 
46 
47 
chronic HCV in the US are unaware of their HCV status 
26, 27
. The introduction of 
48 
49 
50 sensitive and specific point-of-care testing kits in community settings accessed by at- 
51 
52 risk groups would provide healthcare professionals with the tools to rapidly 
53 
54 determine HCV status. Many of the available testing kits circumvent the need for 
55 
56 venipuncture to be performed. This is advantageous given that people who inject 
57 
58 
59 
60 
55 
56 
57 
58 
59 
60 
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1 
2 
3 drugs generally have poor venous access. The use of such testing would enable 
4 
5 case-finding in certain higher prevalence settings. The benefits of point-of-care 
6 
7 
testing, i.e. result available within thirty minutes as compared to a similar sample 
8 
9 
10 being sent to a remote laboratory and available in a few days, are yet to be proven. 
11 
12 The most important issue is how diagnosis leads to treatment and cure. The pathway 
13 
14 to treatment and cure is going to be one of multiple visits to the point of care or other 
15 
16 sites; and the value of an instant test result as opposed to returning at a later date for 
17 
18 
said result must be weighed in the context of entry to treatment, which is yet to be 
20 
21 evaluated. 
22 
23 
24 
25 Given that over half of people who inject drugs in the UK and USA are unaware of 
26 
27 
their true HCV status 
26, 27
, testing at-risk populations to raise the number of people 
28 
29 
30 being treated for HCV is vital to have any chance of achieving HCV elimination. 
31 
32 Previous UK studies evaluating the option of dried blood spot testing within specialist 
33 
34 addiction services and prisons found that HCV testing increased almost six-fold 28, 29. 
35 
36 A recent U.S study reported that in clinics that offer comprehensive screening and 
37 
38 
39 assessment for blood borne viruses, diagnostic rates of HCV soar within these 
40 
41 populations 
30. A 2015 systematic review supports these findings, reporting that the 
42 
43 availability of dried blood spot testing appears to increase the uptake of HCV testing 
44 
45 in high-risk populations 25. Hence, dried blood spot testing is clearly a vital tool in the 
46 
47 
efforts to increase HCV case-finding amongst people who inject drugs. Dried blood 
48 
49 
50 spot testing has also been proven to be suitable for large-scale screening programs 
51 
52 and therapeutic monitoring. As such, it can be employed to increase access to care 
53 
54 30. 
55 
56 
57 
58 
59 
60 
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1 
2 
3 A recent cost-utility analysis utilizing a dynamic mathematical model showed that 
4 
5 increasing HCV case-finding in addiction services can be cost-effective. However, 
6 
7 
this does not translate directly to prison settings. Cost-effectiveness of case-finding 
8 
9 
here depends on continuity of care following release 31. It has been argued that the 
11 
12 U.S criminal justice system represents an ideal focus for HCV case-finding and 
13 
14 treatment, given the high volume of HCV-infected individuals currently in contact with 
15 
16 correctional facilities 
32
. However, some may argue that the way correctional facilities 
17 
18 
operate would worsen treatment outcomes due to high rates of re-infection, 
20 
21 secondary to unacknowledged institutional high risk drug use. Additionally, routes of 
22 
23 reimbursement for treatment costs may make it impossible to establish treatment 
24 
25 programs in prisons in many countries. 
26 
27 
28 
29 
30 A 2015 Canadian study evaluated the health and economic benefits conferred by 
31 
32 incorporating a one-time screening strategy for HCV in various populations. Using a 
33 
34 state-transition model, they proposed that a one-time screening program for pre- 
35 
36 selected age groups would likely be cost-effective as asymptomatic cases of HCV 
37 
38 
39 would be detected. They calculated that this approach could prevent at least 9 HCV- 
40 
41 related deaths per 100,000 persons screened over the lifetime of the cohort 
42 
43 analysed 33. 
44 
45 
46 
47 
So the diagnostic technology to diagnose HCV is reliable, cost-effective and widely 
48 
49 
50 available. The evidence base for modes of delivery of testing is substantial and this 
51 
52 is being translated into effective detection programs in some countries with France 
53 
54 and Australia reporting approximately 80% of their prevalent HCV populations having 
13  
19 
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1 
2 
3 been diagnosed 
34
. So widespread diagnosis of prevalent HCV infection is possible 
4 
5 and has already been achieved in some countries. 
6 
7 
8 
9 
10 Interruption of Transmission 
11 
12 There are multiple potential routes at which we could interrupt transmission of HCV, 
13 
14 including primary prevention of infection and therapy to prevent further transmission. 
15 
16 In primary prevention of HCV, clean needles and syringes are the mainstay but 
17 
18 
developments in vaccination offer some hope for the future. In HCV therapy, 
20 
21 treatment as prevention is dependent not just on the efficacy of the therapy but also 
22 
23 on its effective delivery. 
24 
25 
26 
27 
1.   Primary prevention of infection. 
28 
29 
30 The main driver for new HCV infection is the injection of drugs with contaminated 
31 
32 needles and other injecting paraphernalia 35. Therefore, the provision of clean 
33 
34 
35 needles and other injecting equipment, along with access to opiate replacement 
36 
37 therapy (for opiate users), to reduce injecting frequency, should reduce the risk of 
38 
39 HCV transmission. It has been estimated that prevalence of HCV in the UK could be 
40 
41 up to 60% higher in the absence of opiate substitution therapy and needle and 
42 
43 
syringe programs 36. Hagan et al reported that strategies combining treatment for 
44 
45 
46 substance misuse and instruction for safe injecting practices reduced HCV 
47 
48 seroconversion by 75%. However, they reported that further research is needed to 
49 
50 ascertain what specific interventions are most effective in the different subgroups of 
51 
52 people who inject drugs 37. To complement the Hagan study, Turner et al estimated 
53 
54 
55 that opiate substitution therapy and needle and syringe programs reduce HCV 
56 
57 transmission by 80% in a UK context 
38. Nonetheless, previous modelling has 
58 
59 
60 
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1 
2 
3 suggested that these interventions alone do not prevent incident HCV infections 
4 
5 amongst UK people who inject drug 
36
. Indeed, such programs have demonstrated 
6 
7 
higher success rates for HIV prevention compared to HCV 14, 37. Contributing factors 
8 
9 
10 to this are that HCV is ten times more transmissible than HIV (in the context of 
11 
12 people who inject drugs) and HCV often survives on fomites for prolonged periods of 
13 
14 time 
39
. Despite this, opiate substitution therapy and needle and syringe programs 
15 
16 offer other benefits such as reductions in drug-related deaths and drug-related crime 
17 
18 
as well as protection from other blood borne infections 21, 40. 
20 
21 
22 
23 HCV eradication will likely not be possible without staunch efforts to limit new 
24 
25 infections that are fueling the epidemic. Numerous interventions have evolved over 
26 
27 
the years that serve to decrease transmission rates. As already alluded to, 
28 
29 
30 community-based outreach and education programs, stemming from the HIV 
31 
32 epidemic in the 1980’s, proved beneficial in reducing the prevalence of blood borne 
33 
34 viruses within local populations. Access to free sterile injecting equipment further 
35 
36 contributed to reductions in HIV and HCV transmission. Although HCV remains very 
37 
38 
39 high amongst people who inject drugs, the introduction of anti-HIV interventions had 
40 
41 a profound impact on HCV prevalence 
14. However, such effective public health 
42 
43 interventions are scarce, even in many developed countries. Even where they exist, 
44 
45 funding is poor. Edlin and Winkelstein argue that community interventions must be 
46 
47 
scaled-up if HCV transmission is to be reduced 
39
. In a review on the feasibility of 
48 
49 
50 HCV eradication in the United States, they comment that needle and syringe 
51 
52 programs only operate in 166 U.S cities, with 20 states not running any such 
53 
54 programs at all. They also argue that pharmacies are critical in providing sterile 
55 
56 needles as they would reach all populations, not just a fraction of people who inject 
57 
58 
59 
60 
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1 
2 
3 drugs as it currently stands 
39
. Current U.S legislation in many states restricts access 
4 
5 to sterile needles and syringes for illicit drug-use. This reflects a need for policy 
6 
7 
change in a concerted effort to stem the tide of HCV. Recent changes to Californian 
8 
9 
10 legislation gave more power to local health jurisdictions, with some cities choosing to 
11 
12 legalise non-prescription syringe sales in pharmacies. A 2015 analysis demonstrated 
13 
14 that where it was legal, more syringes were obtained amongst intravenous drug user 
15 
16 populations. Public health policies such as this must be extended to realize the true 
17 
18 
benefits it would have on HCV transmission in target populations 41. However, one 
20 
21 must take into account the varied transmission profiles now being seen in some 
22 
23 developed countries and any public health initiatives for the provision of injecting 
24 
25 equipment must ensure it reaches those at risk. Recent trend analysis has revealed 
26 
27 
an emerging HCV epidemic in the U.S, stemming from chaotic injecting habits and 
28 
29 
30 early prescription opioid abuse. Socioeconomic analysis reveals the epidemic to be 
31 
32 concentrated in non-urban white males, who often have very limited access to sterile 
33 
34 injecting equipment and injecting advice from experienced users 42 as this is 
35 
36 occurring in areas without previous significant injecting drug use. Different patterns of 
37 
38 
39 drug abuse may change the benefits of the treatment as prevention approach. 
40 
41 
42 
43 Although needle-sharing is a major aspect of HCV transmission, other injection 
44 
45 paraphernalia have been strongly implicated in the spread of the virus. For example, 
46 
47 
the sharing of cookers, filtration cotton and water can also permit viral transmission 
48 
49 43
. An earlier study calculated that 54% of HCV infections in people who inject drugs 
51 
52 who did not share needles could be attributed to other injecting equipment 
44. The 
53 
54 provision of sterile paraphernalia in Scotland is anticipated to reduce HCV 
55 
56 transmission amongst people who inject drugs, but results from this natural 
57 
58 
59 
60 
16  
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1 
2 
3 experiment are awaited 
43
. However, earlier studies evaluating the risks of HCV 
4 
5 transmission amongst drug users who share injecting equipment have failed to 
6 
7 
quantify the contribution that this route of infection is having on HCV spread 45. 
8 
9 
10 Indeed, one 2014 study concluded that, although injecting risk behaviour is clearly 
11 
12 reduced by opiate substitution therapy and needle and syringe programs, 
13 
14 comparatively little review-level evidence exists to support such a trend for HCV 
15 
16 transmission amongst people who inject drugs 
46
. 
17 
18 
19 
20 
21 2.   Vaccination 
22 
23 
In most infectious diseases that have been considered for elimination a vaccine has 
24 
25 
26 been available. However, this is not essential as evidenced by the near eradication 
27 
28 of the Guinea worm without even drug therapy 
47. Of course vaccine development 
29 
30 seems logical. It can be reasonably argued that due to the asymptomatic nature of 
31 
32 the virus, and the fact that most people are unaware of their HCV status, vaccination 
33 
34 
is perhaps the most effective way of eradicating HCV 10. A universal vaccine could 
36 
37 not only prevent primary HCV infection, but may also prevent re-infection after cure 
38 
39 following direct-acting antiviral therapy. This latter use has implications for those with 
40 
41 ongoing risk of HCV exposure, such as in people who inject drugs 48. It is estimated 
42 
43 
that even if pricing of direct-acting antivirals were 1,000-fold lower to benefit low- 
44 
45 
46 income nations, the costs of extensive HCV screening and drug distribution would 
47 
48 exceed those of a universal vaccination program 
49. Results from several vaccine 
49 
50 trials are eagerly awaited. In one such study, Swadling et al describe the 
51 
52 development of a highly immunogenic vaccine for HCV. By utilizing the critical role 
53 
54 
55 that T cell immunity plays in antiviral control, they report having produced a potent T 
56 
57 cell vaccine that prevents chronic infection by incorporating chimpanzee adenoviral 
58 
59 
60 
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1 
2 
3 and MVA vectors to prime and boost T cell memory. The first efficacy study of 
4 
5 ChAd3NSmut/MVA-NSmut in IVDU’s has recently started in the U.S (NCT01436357) 
6 
7 50. However, results from these studies are forthcoming and historically, such T cell 
8 
9 
10 vaccines have had more limited efficacy than antibody-based vaccines in clinical 
11 
12 trials. 
13 
14 
15 
16 3.   HCV therapy 
17 
18 
19 HCV antiviral therapy has undergone a revolution, moving very rapidly from IFN- 
20 
21 based therapies with cure rates of 40-70% depending on genotype, to the advent of 
22 
23 
direct-acting antivirals achieving cure rates in excess of 90% for all genotypes with 
24 
25 
26 treatment duration reduced to as little as eight weeks. The development of these 
27 
28 newer antivirals has long been impeded by the lack of an effective cell culture 
29 
30 system for HCV proliferation 51. The availability of high-throughput virological assays 
31 
32 to characterise the various stages of the HCV replication cycle have enabled the 
33 
34 
identification of more specific antiviral targets 52, 53. This development, combined with 
36 
37 changes in the definition of sustained virological response (SVR), has generated the 
38 
39 momentum for the rapid change in the field. The European Association for Study of 
40 
41 Liver (EASL) describes the endpoint of therapy as undetectable HCV RNA 24 weeks 
42 
43 
after the end of the treatment course (SVR24), defined as <15 IU/mL 11. In a long- 
44 
45 
46 term follow-up study of HCV-infected patients treated with PEG-IFN-2a and 
47 
48 ribavirin (n = 1,343), a durable SVR24 of 99.1% was retained once achieved 54. Such 
49 
50 data suggests that HCV recurrence is rare in patients who achieve an SVR, and that 
51 
52 
from a virologic standpoint, such patients can be regarded as cured. The validity of 
54 
55 measuring HCV RNA 12 weeks after completion of treatment (SVR12) has been 
56 
57 
58 
59 
60 
18  
19 
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1 
2 
3 evaluated and approved by regulators in the U.S and Europe, as an equivalent end 
4 
5 point 
11
. 
6 
7 
8 
9 
10 The currently available direct-acting antivirals are split into three classes defined by 
11 
12 their HCV target protein: the protease inhibitors targeted against the NS3/4a 
13 
14 protease; and the NS5a complex inhibitors and polymerase inhibitors, which are 
15 
16 directed against the NS5b protein. This latter class can be further divided into 
17 
18 
nucleotide and non-nucleotide inhibitors. Initial protease inhibitors, and to a lesser 
20 
21 extent NS5a inhibitors, are genotype specific. However, newer pan-genotypic direct- 
22 
23 acting antivirals with superior efficacy, lower adverse effect profiles and shorter 
24 
25 therapy durations are constantly emerging 
13
. 
26 
27 
28 
29 
30 Access to treatment has been widened with the advent of these new drugs. 
31 
32 Previously, IFN-based therapy was contraindicated in patients with many co- 
33 
34 morbidities including decompensated cirrhosis 35. Thus, with the newer antivirals 
35 
36 therapy can now be given to patients in whom it may have previously been 
37 
38 
39 contraindicated. This also applies to populations of people who inject drugs, where 
40 
41 concerns about adherence to safety monitoring was considered a relative 
42 
43 contraindication to therapy, despite studies showing this was not an issue. Currently, 
44 
45 concerns are expressed about how robust the new all-oral regimens are if adherence 
46 
47 
is suboptimal in patients with more chaotic lifestyles, leaving them at risk of 
48 
49 
50 developing viral resistance. To date, trials of direct-acting antivirals in people who 
51 
52 inject drugs have shown that treatment remains highly effective in this population 
55,
 
53 
54 56, 57. The full impact of these newer antivirals will only be appreciated once 
55 
56 
57 
58 
59 
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1 
2 
3 innovative approaches to engage more HCV-infected individuals into antiviral 
4 
5 therapy are practiced. 
6 
7 
8 
9 
10 4.  Delivery of HCV therapy- Pathway to Eradication 
11 
12 The delivery of therapy to patients is key to its efficacy. Complex care pathways, 
13 
14 
based in, or outreaching from secondary or tertiary care, have been developed to 
16 
17 deliver IFN-based therapy to patients. Such care pathways focus on managing the 
18 
19 side effects of therapy safely. Chaotic unstable patients such as people who inject 
20 
21 drugs have not made it through these therapy pathways in significant numbers and 
22 
23 
such patients that do are atypical. The aim of these pathways has been to prevent 
24 
25 
26 advanced liver disease by curing HCV infection before cirrhosis develops. So the 
27 
28 episode of treatment can be delayed until the patient is considered suitable, by the 
29 
30 constraints of the treatment pathway. This is in marked contrast to the situation if 
31 
32 treatment as prevention is the aim of therapy, where early therapy at the earliest 
33 
34 
35 possible time in the duration of infection would give the optimum outcome. So the 
36 
37 pathway to treatment has to be receptive to the patient. 
38 
39 
40 
41 Clinical networks are a much vaunted solution to the problems associated with 
42 
43 
treatment of HCV. In England they are a very secondary care-based solution to allow 
44 
45 
46 patients to be treated at hospitals closer to their locality, but still controlling 
47 
48 availability of drug therapy centrally. In Scotland’s HCV action plan, managed care 
49 
50 networks were a central plank to achieve the integration of primary and secondary 
51 
52 care with third sector providers of health care around patients with or at risk of HCV 
53 
54 
55 into a cohesive and seamless treatment pathway. This integration was fundamental 
56 
57 to the success of the Scottish action plan, the implementation of this is described 
58 
59 
60 
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1 
2 
3 and illustrated in the report by Tait et al 
58
. Thus networks can achieve improvement 
4 
5 in care, particularly when working across healthcare boundaries and accessing 
6 
7 
difficult-to-reach patient populations. However, all key stakeholders in the area need 
8 
9 
10 to be a part of the network, working together to an agreed strategic aim. The MCN 
11 
12 model is ideally suited to a treatment as prevention strategy. 
13 
14 
15 
16 People who inject drugs are a largely stigmatized group who have limited access to 
17 
18 
conventional healthcare. Often as a result of homelessness and deprivation, many 
20 
21 patients lack a means of communication with conventional healthcare providers. 
22 
23 However, they are often in regular contact with other services in a variety of 
24 
25 contexts. For example: needle exchange programs in the community which dispense 
26 
27 
both sterile injecting equipment and advice on safe injecting practices; and 
28 
29 
30 pharmacies which administer methadone to those on opiate substitution programs. 
31 
32 These points of contact represent an ideal opportunity to target people who inject 
33 
34 drugs for HCV treatment. Pilot studies show that with the new direct-acting antivirals, 
35 
36 with their reduced need for regular blood monitoring and fewer side-effects, the 
37 
38 
39 clinical and para-clinical staff within these facilities such as pharmacists and drug 
40 
41 workers are keen and able to take on a lead role in assessment and provision of 
42 
43 anti-HCV therapy as part of managed care networks 59. These managed care 
44 
45 networks provide the clinical supervision they need to deliver a protocol-based HCV 
46 
47 
treatment pathway. The initial sustained virological response rates from such 
48 
49 
50 pathways match clinical trials and are much more inclusive of a broader group of 
51 
52 patients from a background of intravenous drug use, which is vital to a treatment as 
53 
54 prevention strategy. 
55 
56 
57 
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1 
2 
3 In addition to opiate substitution centers (e.g. pharmacies) and needle and syringe 
4 
5 program facilities, prisons should also be considered as an opportunity to treat. 
6 
7 
Given the high numbers and proportions of people who inject drugs in correctional 
8 
9 
10 facilities, prisoners represent an ideal target population for treatment as prevention. 
11 
12 As with targeting people who inject drugs in general, targeting prisoners poses its 
13 
14 own challenges and ethical considerations. A 2015 letter by Levy and Larney 
15 
16 highlighted the issues of treatment as prevention in correctional settings. They argue 
17 
18 
that the imbalance of power between prisoners and custodial staff may translate to a 
20 
21 curtailing of civil liberties 
60. In such circumstances, how can we be sure that consent 
22 
23 to screening and treatment is truly voluntary? Adding to this, Martin and colleagues 
24 
25 emphasize the need for continuity of care amongst prisoners after release or transfer 
26 
27 
for this approach to HCV prevention to be cost-effective 
61
. A recent review of 
28 
29 
30 treatment outcomes in prisoners treated in Scotland has shown a strong negative 
31 
32 correlation between liberation during treatment and sustained virological response. 
33 
34 This work was using IFN-based therapy and so should be less of an issue with new 
35 
36 direct-acting antiviral-based therapy of shorter duration 
62
. In terms of primary 
37 
38 
39 prevention Levy and Larney also called for greater access to harm reduction 
40 
41 services such as needle exchange programs within prisons, arguing that such 
42 
43 services exist in community settings for people who inject drugs. As such, those who 
44 
45 successfully complete treatment can protect themselves from re-infection and thus 
46 
47 
increase the effectiveness of this HCV eradication strategy 
60
. It should be noted, 
48 
49 
50 however, that a 2013 study found that in a sample of 5,076 surveyed prisoners in 
51 
52 Scotland, the risk of HCV transmission was lower amongst prisoners compared to 
53 
54 Scottish people who inject in the community. The authors propose that this is due to 
55 
56 the low incidence of in-prison injecting, although they concede that some under- 
57 
58 
59 
60 
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1 
2 
3 reporting is likely. As such, the authors suggest that low HCV incidence amongst 
4 
5 prison populations does not depend on the introduction of needle exchange 
6 
7 
programs 63. The major issue around provision of needle exchange in prisons is the 
8 
9 
10 potential for their use as weapons against staff which has led prison officer unions to 
11 
12 object on health and safety grounds. 
13 
14 
15 
16 The major criticism of treatment as prevention strategies in people who inject drugs 
17 
18 
is the impact on injecting behaviour and the risk of re-infection. Regarding the 
20 
21 interplay between HCV treatment and the behaviours of intravenous drug users, it 
22 
23 has been established that antiviral therapy does not increase illicit drug use. 
24 
25 Intermittent injecting during treatment has also been shown to have no influence 
26 
27 
over regimen adherence, completion of treatment, or attainment of sustained 
28 
29 
30 virological responses. Contrary to this, more regular injecting has been associated 
31 
32 with lower sustained virological response rates and discontinuation of treatment 
14. In 
33 
34 an effort to better understand injecting behaviours and how they relate to re-infection 
35 
36 risk post-sustained virological response, Valerio and colleagues conducted an 
37 
38 
39 analysis of 1,170 people who inject drugs who attained a sustained virological 
40 
41 response over a twenty-year period (1992-2012) 
64. They reported that an increasing 
42 
43 minority of people who inject drugs who attain a sustained virological response are at 
44 
45 an elevated risk of re-infection or death as a result of high intensity injecting 
46 
47 
behaviour. In agreement with EASL recommendations 
11
, the authors advocate for 
48 
49 
the on-going monitoring of high-risk patients post-sustained virological response 
64
. 
51 
52 However, evidence suggests that people who inject drugs who achieve a sustained 
53 
54 virological response are more likely to pursue a healthy lifestyle 65. The Valerio study 
55 
56 also voiced concern that re-infection rates amongst people who inject drugs will rise 
57 
58 
59 
60 
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1 
2 
3 as HCV treatment is scaled-up 
64
. Commentary from Hellard and Scott (2015) 
4 
5 postulated that many of the current models measuring the outcomes of HCV 
6 
7 
treatment as prevention incorporate high levels of re-infection into their modelling, 
8 
9 
10 thus overstating the re-infection risk. Whilst it is established that HCV re-infection is 
11 
12 common out-with treatment settings, re-infection after antiviral therapy is 
13 
14 considerably lower 
66
. A meta-analysis by Aspinall et al calculated the pooled risk of 
15 
16 re-infection amongst five cohorts of people who inject drugs (n = 131) to be 2.4 (CI = 
17 
18 
0.9-6.1) per 100 person years 67. However, a 2016 study reported an 11% re- 
20 
21 infection rate in a multicentre trial follow-up of intravenous drug users infected with 
22 
23 genotypes 2 or 3 68. This highlights possible variations in the range of reinfections. 
24 
25 Emergent data from the ERADICATE trial will provide more information on 
26 
27 
reinfection rates in people who inject drugs undergoing anti-HCV therapy. A more 
28 
29 
30 recent study suggested that targeting HCV treatment by stratifying the level of 
31 
32 injection drug-use could enhance benefits at the population level 
69. The authors 
33 
34 reported that HCV treatment is best determined by its prevalence within the 
35 
36 population; when >50% of all exchanged syringes are contaminated with HCV they 
37 
38 
39 recommend treating low-risk people who inject drugs first. Conversely, below this 
40 
41 threshold, treating high-risk intravenous drug users first appeared to produce the 
42 
43 greatest societal benefits 69. Indeed, it has been shown that targeting the injecting 
44 
45 network provides greater population health benefit than treating people who inject 
46 
47 
drugs randomly for their HCV 
70
.  Studies such as this support the idea that people 
48 
49 
50 who inject drugs should not be excluded from treatment based on their apparently 
51 
52 risky behaviour. A further study by Martin and colleagues suggested that treating 
53 
54 current injectors is more cost-effective than treating ex- or non-injectors when the 
55 
56 chronic HCV prevalence is less than 60% 71. 
57 
58 
59 
60 
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1 
2 
3 
4 
5 Eradication – Is It Cost-Effective? 
6 
7 
8 Relative to the expense of long-term complications associated with HCV infection, 
9 
10 the price of direct-acting antivirals is considered cost-effective 22. The bulk of the 
11 
12 health costs and health consequences associated with HCV infection are due to end 
13 
14 
stage liver disease late in the natural history of infection. This has led some to 
15 
16 
17 suggest that treatment should be restricted to patients with more advanced disease 
18 
19 only. As even in high-income nations the cost of direct-acting antivirals may prohibit 
20 
21 their widespread uptake, due to affordability, relative to other demands on health 
22 
23 budgets. Cost-effective evaluations are needed to verify how best to allocate 
24 
25 
26 resources and services. A 2015 study aimed to forecast population-level outcomes 
27 
28 from alternative treatment strategies in a resource-rich setting 
72. Using a simulation 
29 
30 model and projecting outcomes to 2030, trends in HCV incidence and severe liver 
31 
32 morbidity was extrapolated according to treatment strategies that prioritised either 
33 
34 
people who inject drugs or patients with moderate/advanced liver fibrosis. The 
35 
36 
37 authors concluded that no single approach to the treatment of HCV in an era of IFN- 
38 
39 free therapies addressed all public health concerns. Prioritising people who inject 
40 
41 drugs for treatment results in substantially reduced HCV incidence and transmission 
42 
43 rates in the population, but fails to address the impact of liver disease. Conversely, 
44 
45 
46 suboptimal reductions in HCV incidence occurs when those with moderate/advanced 
47 
48 liver disease are targeted for priority treatment. It is projected that by specifically 
49 
50 targeting active intravenous drug users, incident HCV infection can be reduced to 
51 
52 <50 cases per year by 2025 
72
. The conclusion that can be drawn from this paper 
53 
54 
was that a twin track strategy that targeted active injectors and those with evidence 
56 
57 of hepatic fibrosis would be most cost-effective, but would leave the short fall in 
58 
59 
60 
25  
19 
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1 
2 
3 treatment on those with mild disease who were not injecting, a strategy that may not 
4 
5 be acceptable to the general population. These estimates support the previous 
6 
7 
modelling studies by Martin and colleagues described above. The high cost of anti- 
8 
9 
10 HCV therapy makes a more targeted treatment approach more economically 
11 
12 beneficial. As such, epidemiological data on injector populations must be upgraded 
13 
14 on a country by country basis to allow a planned strategy 
73
. As already discussed, it 
15 
16 is unlikely that substantial reductions in HCV prevalence would be achievable with 
17 
18 
opiate substitution therapy and needle and syringe programs alone. However, 
20 
21 expansion of these interventions would reduce the number of people who inject 
22 
23 drugs requiring HCV treatment, and be highly cost-effective thus making a target 
24 
25 HCV prevalence reduction easier to achieve 
14
. This supports the idea that HCV 
26 
27 
eradication policy must be built upon scaled-up community outreach projects. While 
28 
29 
30 the health economic analysis supports the idea of treatment as prevention, and 
31 
32 shows it to be cost effective, it may not be achievable due to the affordability issues 
33 
34 surrounding such a relatively common disease with such a currently expensive 
35 
36 therapy. There is already prioritisation of HCV therapy for patients with advanced 
37 
38 
39 fibrosis in many countries, with patients with milder disease waiting for therapy. To 
40 
41 further prioritise active intravenous drug users over other patients with mild disease 
42 
43 may not be acceptable to health care providers and payers. 
44 
45 
46 
47 
Conclusion 
49 
50 The growing burden of chronic HCV infection presents a significant public health 
51 
52 concern. With the advent of highly efficacious and tolerable direct-acting antivirals, 
53 
54 
the concept of treatment as prevention is gaining credence and efforts to scale-up 
56 
57 access to treatment have been developed. 
58 
59 
60 
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1 
2 
3 
4 
5 Although global eradication of HCV via targeted treatment is highly desirable, current 
6 
7 
limitations render it improbable at this point in time; with regional elimination being a 
8 
9 
10 more realistic prospect. Sub-optimal coverage of harm reduction services worldwide, 
11 
12 the lack of an effective vaccine, and the high baseline HCV prevalence in many 
13 
14 places makes HCV eradication very difficult to accomplish. Despite this, modelling 
15 
16 studies by Martin and colleagues show that lower treatment uptake is required to 
17 
18 
achieve a more substantial reduction in HCV prevalence when the baseline 
20 
21 prevalence is below a certain threshold. Increased access to harm reduction 
22 
23 services may drive the local HCV prevalence low enough to allow targeted treatment 
24 
25 to be successful. 
26 
27 
28 
29 
30 Perhaps the most important prevention strategy is the implementation of HCV testing 
31 
32 so as to identify those in need of treatment. Solutions must be formulated to 
33 
34 overcome barriers to care. In this way, more patients eligible to be treated are 
35 
36 identified and managed accordingly. Early identification, using more accurate 
37 
38 
diagnostic tools, will be essential to prevent the onward transmission of HCV 
10
. 
40 
41 
42 
43 Although technically feasible, HCV eradication will require a galvanised effort from 
44 
45 not only practitioners and healthcare policy makers, but also the patients 
46 
47 
themselves. To achieve HCV eradication via treatment on a global scale, people who 
48 
49 
50 inject drugs must be given increased access to affordable treatment.  Ensuring 
51 
52 affordability of anti-HCV therapy will be critical in the pursuit of eradicability. 
53 
54 
55 
56 
57 
58 
59 
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